Comment on the contribution by Souayah et al., "Guillain-Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009"

Vaccine

Volumn 29, Issue 5, 2011, Pages 865-866

  Slade, Barbara A ^a   Gee, Julianne ^a   Broder, Karen R ^a   Vellozzi, Claudia ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; LETTER; MEDICAL RECORD; PRIORITY JOURNAL; VACCINATION;

GUILLAIN-BARRE SYNDROME; HUMANS; PAPILLOMAVIRUS VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 78751584926     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.031     Document Type: Letter

References (13)

1. Souayah N., Michas-Martin P.A., Nasar A., Krivitskaya N., Yacoub H.A., Khan H., et al. Guillain-Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009. Vaccine 2010, 10.1016/j.vaccine.2010.09.2010.
2. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect J 2004, 23:287-294.
3. Ellenberg S.S., Chen R.T. The complicated task of monitoring vaccine safety. Public Health Rep 1997, 112(1):10-20.
4. Singleton J.A., Lloyd J.C., Mootrey G.T., Salive M.E., Chen R.T. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 1999, 17:2908-2917.
5. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Southerland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(7):750-757.
6. Sejvar J, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. doi:10.1016/j.vaccine.2010.06.003.
7. DeStefano F. The vaccine safety datalink project. Pharmacoepidemiol Drug Safe 2001, 10(5):403-406. Vaccine Safety Datalink Group.
8. Rosenthal S., Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995, 85(12):1706-1709.
9. Dorell C., Stokley S., Yankey D., Cohn A. National State and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2010, 59(32):1018-1021.
10. CDC, unpublished data.
11. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.R., et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110(2):105-123.
12. Institute of Medicine. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington, DC: National Academy Press; 1994. http://www.nap.edu/catalog/2138.html.
13. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A., et al. The vaccine adverse events reporting system (VAERS). Vaccine 1994, 12(6):542-550.